Skip NavigationSkip to Content

The novel fold of scytovirin reveals a new twist for antiviral entry inhibitors

  1. Author:
    McFeeters, R. L.
    Xiong, C. Y.
    O'Keefe, B. R.
    Bokesch, H. R.
    McMahon, J. B.
    Ratner, D. M.
    Castelli, R.
    Seeberger, P. H.
    Byrd, R. A.
  2. Author Address

    Natl Canc Inst, Struct Biophys Lab, Frederick, MD 21702 USA. Natl Canc Inst, Mol Targets Dev Program, Frederick, MD 21702 USA. Natl Canc Inst, SAIC Frederick, Frederick, MD 21702 USA. MIT, Dept Chem, Cambridge, MA 02139 USA. ETH, Swiss Fed Inst Technol, Organ Chem Lab, CH-8092 Zurich, Switzerland.;Byrd, RA, Natl Canc Inst, Struct Biophys Lab, Frederick, MD 21702 USA.;rabyrd@ncifcrf.gov
    1. Year: 2007
    2. Date: Jun
  1. Journal: Journal of Molecular Biology
    1. 369
    2. 2
    3. Pages: 451-461
  2. Type of Article: Article
  3. ISSN: 0022-2836
  1. Abstract:

    The solution structure of the potent 95 residue anti-HIV protein scytovirin has been determined and two carbohydrate-binding sites have been identified. This unique protein, containing five structurally important disulfide bonds, demonstrates a novel fold with no elements of extended regular secondary structure. Scytovirin contains two 39 residue sequence repeats, differing in only three amino acid residues, and each repeat has primary sequence similarity to chitin binding proteins. Both sequence repeats form similarly structured domains, with the exception of one region. The result is two carbohydrate-binding sites with substantially different affinities. The unusual fold clusters aromatic residues in both sites, suggesting a binding mechanism similar to other known hevein-like carbohydrate-binding proteins but differing in carbohydrate specificity. Scytovirin, originally isolated from the cyanobacterium Scytonema varium, holds potential as an HIV entry inhibitor for both therapeutic and prophylactic anti-HIV applications. The high-resolution structural studies reported are an important initial step in unlocking the therapeutic potential of scytovirin. (C) 2007 Elsevier Ltd. All rights reserved.

    See More

External Sources

  1. DOI: 10.1016/j.jmb.2007.03.030
  2. WOS: 000246757600014

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel